Literature DB >> 16335862

Potent gastric acid inhibition in Helicobacter pylori eradication.

Javier P Gisbert1.   

Abstract

At present, antisecretory drugs--foremost among them the proton pump inhibitors (PPIs)--represent a keystone in Helicobacter pylori eradication therapy. The present article shall first compare the role of PPIs as compared with histamine H2 receptor antagonists, both of them in the role of antibiotic-associated antisecretory therapy, and shall then address the contribution of each of the various PPIs that have been developed until the present time to the H. pylori eradication therapies. In summary, it may be concluded that PPIs are more effective overall than H2 receptor antagonists when the two groups of antisecretory drugs are given at the usual standard doses together with antibiotics with the intention of eradicating H. pylori infection. However, all PPIs (omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole) are equivalent when given together with two antibiotics to cure the infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16335862     DOI: 10.2165/00003495-200565001-00012

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  121 in total

Review 1.  [Treatment for the eradication of Helicobacter pylori. Recommendations of the Spanish Consensus Conference].

Authors:  J P Gisbert; X Calvet; F Gomollón; R Sáinz
Journal:  Med Clin (Barc)       Date:  2000-02-12       Impact factor: 1.725

Review 2.  Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.

Authors:  C A Stedman; M L Barclay
Journal:  Aliment Pharmacol Ther       Date:  2000-08       Impact factor: 8.171

3.  Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori.

Authors:  N Chiba; C P Marshall
Journal:  Can J Gastroenterol       Date:  2000-01       Impact factor: 3.522

4.  The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection.

Authors:  P O Erah; A F Goddard; D A Barrett; P N Shaw; R C Spiller
Journal:  J Antimicrob Chemother       Date:  1997-01       Impact factor: 5.790

Review 5.  Pantoprazole: a new proton pump inhibitor.

Authors:  P W Jungnickel
Journal:  Clin Ther       Date:  2000-11       Impact factor: 3.393

Review 6.  Helicobacter pylori therapy: first-line options and rescue regimen.

Authors:  J P Gisbert; J M Pajares
Journal:  Dig Dis       Date:  2001       Impact factor: 2.404

7.  Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection.

Authors:  G V Ohning; R C Barbuti; T O Kovacs; B Sytnik; T J Humphries; J H Walsh
Journal:  Aliment Pharmacol Ther       Date:  2000-06       Impact factor: 8.171

Review 8.  Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.

Authors:  A B Thomson
Journal:  Curr Gastroenterol Rep       Date:  2000-12

Review 9.  Rabeprazole.

Authors:  A Prakash; D Faulds
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

10.  Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.

Authors:  M Hartmann; U Theiss; R Huber; R Lühmann; H Bliesath; W Wurst; P W Lücker
Journal:  Aliment Pharmacol Ther       Date:  1996-06       Impact factor: 8.171

View more
  4 in total

1.  Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.

Authors:  Luyi Chen; Jiamin He; Lan Wang; Qiwei Ge; Hua Chu; Yujia Chen; Xiaoli Chen; Yanqin Long; Yanyong Deng; Huiqin He; Aiqing Li; Shujie Chen
Journal:  Clin Exp Med       Date:  2018-06-06       Impact factor: 3.984

Review 2.  Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.

Authors:  Claudine M Baldwin; Susan J Keam
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

3.  Protective effects of a triple-fermented barley extract (FBe) against HCl/EtOH-induced gastric mucosa damage in mice.

Authors:  Jong-Min Lim; Chang-Hyun Song; Su-Jin Park; Dong-Chan Park; Hyung-Rae Cho; Go-Woon Jung; Khawaja Muhammad Imran Bashir; Sae Kwang Ku; Jae-Suk Choi
Journal:  Food Sci Nutr       Date:  2018-10-01       Impact factor: 2.863

4.  Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pylori.

Authors:  Lili Yang; Ao Zou; Huihua Wu; Hai Guo; Fangting Zhang; Bing Zou; Junping Wang
Journal:  Biomed Res Int       Date:  2021-04-10       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.